<DOC>
	<DOCNO>NCT00741429</DOCNO>
	<brief_summary>The main purpose trial evaluate pulmonary function subject complete one 4 MKC parent trial ( MKC-TI-009 , MKC-TI-102 , MKC-TI-103 , MKC-TI-030 ) additional 2-month safety follow-up .</brief_summary>
	<brief_title>A 2-Month Safety Follow-Up Trial</brief_title>
	<detailed_description>This 2-month safety follow-up study subject MannKind protocols MKC-TI-009 , MKC-TI-102 , MKC-TI-103 MKC-TI-030 . No study medication administer trial . The adverse event data include combined Safety population irrespective previous treatment parent trial .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Subjects complete 4 MKC parent trial ( MKCTI103 , MKCTI009 , MKCTI102 , MKCTI030 ) Urine cotinine test less equal 100 ng/mL Written inform consent Subjects start smoke 4 week followup phase parent trial Subjects begin new inhaled insulin regimen investigational drug 4 week followup phase parent trial and/or participation another clinical trial Female subject pregnant , lactate plan become pregnant Subjects positive urine drug screen Visit 1 Female subject childbearing potential practicing adequate birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>